oral medication glp 1 GLP-1s rapidly expanding user base Lilly's Oral GLP-1 Foundayo Outperforms

On August 28, 2024, Eli Lilly and Company submitted anominationto request that its GLP-1 product, tirzepatide, be added to FDAs Demonstrable Difficulties for Compounding (DDC) lists.

Insurers have plenty to consider when weighing coverage fornew weight loss medications, andthat includes the need tocarefully coordinate distribution with their pharmacy benefit m | Payers need to work closely with PBMs to coordinate coverage decisions about Ozempic and other weight loss drugs, a new guide advises.

This study, together with a companion manuscript, shows that in mice, weight loss as a result of GIP receptor antagonism requires and potentiates functional GLP-1 receptor signalling in the brain, explaining how both GIP receptor agonists and antagonists trigger weight loss through different mechanisms.

Designed specifically for newborn care specialists, this webinar will help identify some commonly asked questions about COVID-19 and GLP-1 medications, apply []

Learn the risks of unregulated meds and safer, cheaper options for your PT patients.